These cases included a head and neck cancer patient with a FANCL p.Tyr111Cys missense mutation who received the PARP-inhibitor olaparib for 12 months until progress, and a patient with a FGFR4 amplified (gene copy number, GCN:4.5) soft-tissue tumor who received the FGFR-inhibitor ponatinib for 1 month until progress (Figure 4A). This evidence concerns the gene FANCL and head and neck cancer.